Table 2.

Clinical trials testing the efficacy of cardiometabolic drugs in reducing EAT volume or thickness

Drug class	Drug name	Follow-up (weeks)	EAT change (%)	Ref.
GLP1R agonists	Liraglutide	24	–42	126
	Liraglutide or exenatide	18	–13	128
	Semaglutide	12	–20	127
	Liraglutide	12	–29	129
	Dulaglutide	12	–20	127
SGLT2 inhibitors	Dapagliflozin	24	–20	136
	Dapagliflozin	24	–10	138
	Canagliflozin	24	–20	139
	Ipragliflozin	12	–12	140
	Luseogliflozin	12	–5	141
	Empagliflozin	24	–5 mla	137
Statins	Atorvastatin	24	–10	148
	Atorvastatin	48	–3	149
	Simvastatin	24	–3	148
	Pravastatin	48	–0.8	149

EAT, epicardial adipose tissue; GLP1R, glucagon-like peptide 1 receptor; SGLT2, sodium–glucose co-transporter 2. ^aAbsolute EAT volume decrease from baseline.